H2BC11 antibody targets histone H2B type 1-C/E/F/G/I (H2BC11), a core component of nucleosomes that play a critical role in chromatin structure and epigenetic regulation. Histone H2B, along with H2A, H3. and H4. forms the octameric core around which DNA is wrapped, influencing DNA compaction, replication, and repair. The H2BC11 variant, encoded by the HIST1H2BC gene in humans, belongs to the histone H2B family and is involved in transcriptional regulation, chromatin dynamics, and cell cycle progression. Post-translational modifications (PTMs) of H2B, such as ubiquitination, phosphorylation, and acetylation, are key to modulating chromatin accessibility and gene expression. Antibodies against H2BC11 are widely used in epigenetics research to investigate histone modification patterns, nucleosome organization, and their implications in diseases like cancer, neurodegeneration, and developmental disorders. These antibodies enable techniques such as chromatin immunoprecipitation (ChIP), Western blotting (WB), and immunofluorescence (IF) to map histone localization, study PTM crosstalk, and assess chromatin remodeling mechanisms. Specificity validation via knockdown/knockout controls or peptide competition assays is essential due to high sequence homology among H2B isoforms. H2BC11 antibodies contribute to understanding how histone variants and their modifications regulate cellular identity, stress responses, and disease pathways, bridging gaps between chromatin biology and therapeutic discovery.